Improving diabetes management through AI and telemonitoring
Better Risk Perception Via Patient Similarity to Control Hyperglycemia and Sustained by Telemonitoring
NA · SingHealth Polyclinics · NCT06607497
This study is testing whether using an AI tool with home monitoring can help people with poorly controlled Type 2 diabetes manage their condition better than just having a regular risk communication session.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 360 (estimated) |
| Ages | 36 Years to 65 Years |
| Sex | All |
| Sponsor | SingHealth Polyclinics (other) |
| Locations | 1 site (Singapore) |
| Trial ID | NCT06607497 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance diabetes management by comparing the effectiveness of an AI-enabled risk communication tool (PERDICT.AI) combined with home-based diabetes monitoring (PTEC-DM) against a standalone risk communication session. The focus is on improving health outcomes such as risk perception, medication adherence, self-care activities, and glycaemic control among patients with poorly controlled Type 2 Diabetes Mellitus. By addressing both risk communication and monitoring, the study seeks to empower patients to make informed health decisions and reduce the risk of diabetes-related complications.
Who should consider this trial
Good fit: Ideal candidates are adults aged 36 to 65 years with poorly controlled Type 2 Diabetes Mellitus who have been under follow-up for at least 12 months.
Not a fit: Patients who are not Singapore citizens or permanent residents, or those with severe health conditions such as end-stage kidney disease or cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve diabetes management and reduce the risk of complications for patients.
How similar studies have performed: Other studies have shown promise in using technology for diabetes management, indicating that this approach could be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 2 Diabetes Mellitus on follow-up at the study site for at least 12 months * Age 36 to 65 years * At least one HbA1c reading ≥ 8.0% within the last 6 months * Able to read and speak English Exclusion Criteria: * Not a Singapore citizen or permanent resident * Pregnant * End-stage kidney disease or on renal replacement therapy * Known terminal illness * Visual and/or hearing impairment * Cognitive impairment or mental illness * Unable to provide informed consent
Where this trial is running
Singapore
- SingHealth Polyclinics — Singapore, Singapore (RECRUITING)
Study contacts
- Principal investigator: Ngiap Chuan Tan, MMed — SingHealth Polyclinics
- Study coordinator: Kalaipriya Gunasekaran, MD
- Email: kalaipriya.gunasekaran@singhealth.com.sg
- Phone: (65)98071122
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetes Mellitus, Type 2